Cargando…

Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck

Squamous cell cancer of the head and neck (SCCHN) is the sixth leading cause for cancer deaths worldwide. Despite extense knowledge of risk factors and pathogenesis about 50 percent of all patients and essentially every patient with metastatic SCCHN eventually die from this disease. We analyzed the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoellein, Alexander, Pickhard, Anja, von Keitz, Fabienne, Schoeffmann, Stephanie, Piontek, Guido, Rudelius, Martina, Baumgart, Anja, Wagenpfeil, Stefan, Peschel, Christian, Dechow, Tobias, Bier, Henning, Keller, Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2011
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248211/ https://www.ncbi.nlm.nih.gov/pubmed/21865609

Ejemplares similares

The response of head and neck squamous cell carcinoma to cetuximab treatment depends on Aurora kinase A polymorphism
por: Pickhard, Anja, et al.
Publicado: (2014)

The Aurora-Kinase A Phe31-Ile polymorphism as possible predictor of response to treatment in head and neck squamous cell carcinoma
por: Baumann, Alexander, et al.
Publicado: (2018)

Inhibition of SphK1 reduces radiation-induced migration and enhances sensitivity to cetuximab treatment by affecting the EGFR/SphK1 crosstalk
por: Schiefler, Carlotta, et al.
Publicado: (2014)

High NOTCH1 mRNA Expression Is Associated with Better Survival in HNSCC
por: Wirth, Markus, et al.
Publicado: (2018)

Bradykinin Receptor B1 and C-Reactive Protein as Prognostic Factors for Pharyngocutaneous Fistula Development After Laryngectomy
por: Koob, Isabelle, et al.
Publicado: (2019)

Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation
por: Koch, Dominik Thomas, et al.
Publicado: (2017)

Cks1 Is Required for Tumor Cell Proliferation but Not Sufficient to Induce Hematopoietic Malignancies
por: Kratzat, Susanne, et al.
Publicado: (2012)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways
por: Pickhard, Anja C, et al.
Publicado: (2011)

Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL
por: Herrmann, Ken, et al.
Publicado: (2014)

An adult patient with Nijmegen Breakage Syndrome and Hodgkin's Lymphoma
por: Engel, Katharina, et al.
Publicado: (2014)

Design, synthesis and biological activity of N(4)-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase
por: Kurup, Sonali, et al.
Publicado: (2017)

Primary tumor-associated expression of CXCR4 predicts formation of local and systemic recurrency in head and neck squamous cell carcinoma
por: Knopf, Andreas, et al.
Publicado: (2017)

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2020)

Report on Late Toxicity in Head-and-Neck Tumor Patients with Long Term Survival after Radiochemotherapy
por: Buchberger, Anna Maria Stefanie, et al.
Publicado: (2021)

Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer
por: Posch, Doris, et al.
Publicado: (2016)

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer
por: Thariat, Juliette, et al.
Publicado: (2008)

A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells
por: Landi, Nicola, et al.
Publicado: (2023)

The role of psycho-oncologic screenings in the detection and evaluation of depression in head and neck cancer aftercare patients
por: Hadas, Stefan, et al.
Publicado: (2021)

Membrane Hsp70—A Novel Target for the Isolation of Circulating Tumor Cells After Epithelial-to-Mesenchymal Transition
por: Breuninger, Stephanie, et al.
Publicado: (2018)

The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
por: Sickmier, E. Allen, et al.
Publicado: (2016)

Targeting Aurora B kinase with Tanshinone IIA suppresses tumor growth and overcomes radioresistance
por: Li, Ming, et al.
Publicado: (2021)

Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer
por: Loeffelbein, Denys J, et al.
Publicado: (2014)

Phase II Trial of CDX-3379 and Cetuximab in Recurrent/Metastatic, HPV-Negative, Cetuximab-Resistant Head and Neck Cancer
por: Bauman, Julie E., et al.
Publicado: (2022)

Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck
por: Merlano, Marco, et al.
Publicado: (2007)

The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Tejani, Mohamedtaki A, et al.
Publicado: (2010)

Cetuximab: its unique place in head and neck cancer treatment
por: Specenier, Pol, et al.
Publicado: (2013)

Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab
por: Patel, Akshar N., et al.
Publicado: (2012)

Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines
por: Kneissl, Julia, et al.
Publicado: (2016)

In vivo hematopoietic Myc activation directs a transcriptional signature in endothelial cells within the bone marrow microenvironment
por: Franke, Katharina, et al.
Publicado: (2015)

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines
por: De Pauw, Ines, et al.
Publicado: (2018)

Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
por: Iida, Mari, et al.
Publicado: (2014)

Bilateral versus ipsilateral neck dissection in oral and oropharyngeal cancer with contralateral cN0 neck
por: Knopf, Andreas, et al.
Publicado: (2020)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
por: Knutzen, Greg, et al.
Publicado: (2015)

High incidence of cetuximab-related infusion reactions in head and neck patients
por: Palomar Coloma, Virginia, et al.
Publicado: (2018)

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma
por: Leblanc, Olivia, et al.
Publicado: (2020)

Cetuximab and anemia prevention in head and neck cancer patients undergoing radiotherapy
por: Maahs, Lucas, et al.
Publicado: (2022)

Therapeutic implications of tumor free margins in head and neck squamous cell carcinoma
por: Backes, Clara, et al.
Publicado: (2017)

Aurora /
por: López Colomé, Pura, 1952-
Publicado: (1994)

Aurora
por: Böhme, Jacob
Publicado: (1979)

Cannot write session to /tmp/vufind_sessions/sess_15vj8elbov9auas5nvkkj5faf4